title: Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
abstract: The management of chemotherapy-induced nausea and emesis presents a major problem in children with cancer. The anti-emetic properties of the 5-HT3 receptor antagonist ondansetron are well documented in adults receiving cytotoxic chemotherapy. Experience in the treatment of children is still limited. Here we present a review of the literature on the anti-emetic treatment with ondansetron in children. Moreover, we provide recommendations on the use of ondansetron during anti-neoplastic chemotherapy and radiotherapy in pediatric oncology.
authors.affiliation: St Anna Children's Hospital, Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Zoubek
authors.forename: M
authors.initials: M
authors.lastname: Kronberger
authors.forename: A
authors.initials: A
authors.lastname: Puschmann
authors.forename: H
authors.initials: H
authors.lastname: Gadner
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007223:Infant; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects*; D012702:Serotonin Antagonists; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D012702:Serotonin Antagonists; D017294:Ondansetron